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We would like to thank Gallina et al. for their letter and appreciation of our manuscript.[1] Indeed, 
our aim was both to report our specific data while also eliciting the experiences of other centers and 
groups. 
Our study,[2] arising from the point of view of a Pathology unit, allowed us to evaluate the 
comprehensive surgical oncology activity of our Institution, but it is really interesting to read about 
the other side of the coin: how it was possible from a clinical point of view to preserve the quality 
and quantity of surgical procedures despite the COVID-19 pandemic. A report from a Thoracic 
Surgery division is especially relevant considering the potential consequences of a SARS-CoV-2 
infection in these fragile patients.  
These suggestions will hopefully help address the present new wave of infections[3] and we think 
this is a critical issue. Considered that for the foreseeable future we will have to deal with 
intermittent lockdowns and ongoing limitations affecting multiple healthcare activities (e.g., 
elective surgery, outpatient practice,…), it will be extremely important to safeguard cancer care 
starting from preserving screening protocols and prompt diagnostic/therapeutic procedures. Their 
interruptions or even delays can lead to severe consequences in the coming years for both patients’ 
outcomes and financial sustainability.[4, 5] 
Regarding future research outlooks, it will be important to comprehensively evaluate the overall 
consequences of the COVID-19 pandemic on surgical oncology practice, also to estimate its 
potential impact on cancer care in the coming years and design possible coping strategies. 
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